Table 1.
Baseline Clinical Characteristics of Patients Treated With Anthracyclines, Taxanes, and Trastuzumab Who Developed or Did Not Develop Cardiotoxicity
| Variable | Entire Cohort (n=81) | Cardiotoxicity (n=26) | No Cardiotoxicity (n=55) | P Value |
|---|---|---|---|---|
| Age, y | 50 ± 10 | 49 ± 10 | 50 ± 10 | 0.78 |
| Dose of anthracyclines | ||||
| Doxorubicin 240 mg/m2 | 71 (88%) | 22 (85%) | 49 (89%) | 0.57 |
| Epirubicin 300 mg/m2 | 10 (12%) | 4 (15%) | 6 (11%) | |
| Radiotherapy | 49 (60%) | 13 (50%) | 36 (65%) | 0.22 |
| Side of breast cancer | ||||
| Right | 34 (42%) | 11 (42%) | 23 (42%) | 0.61 |
| Left | 41 (51%) | 12 (46%) | 29 (53%) | |
| Both | 6 (7%) | 3 (11%) | 3 (5%) | |
| CV risk factors | ||||
| HTN | 26 (32%) | 8 (31%) | 18 (33%) | 0.75 |
| DM | 1 (1%) | 1 (4%) | 0 (0%) | 0.32 |
| Hyperlipidemia | 18 (22%) | 6 (23%) | 12 (22%) | 0.90 |
| Smoking | 6 (7%) | 2 (8%) | 4 (7%) | 0.95 |
| CV treatment | ||||
| ACE inhibitor | 14 (17%) | 6 (23%) | 8 (14%) | 0.36 |
| β-blockers | 9 (11%) | 4 (15%) | 5 (9%) | 0.45 |
| BMI, kg/m2 | 26 ± 5 | 26 ± 9 | 25 ± 6 | 0.77 |
| SBP, mm Hg | 124 ± 19 | 123 ± 17 | 124 ± 20 | 0.77 |
| DBP, mm Hg | 73 ± 10 | 74 ± 11 | 73 ± 10 | 0.93 |
| Heart rate, beats per minute | 71 ± 11 | 71 ± 10 | 70 ± 11 | 0.75 |
| LVEF | 64 ± 5 | 64 ± 4 | 64 ± 6 | 0.82 |
CV indicates cardiovascular; HTN, hypertension; DM, diabetes mellitus; ACE, angiotensin-converting enzyme; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; and LVEF, left ventricular ejection fraction.